Harel Insurance Investments & Financial Services Ltd. in Abbott Laboratories Limited


Opinions of the company Harel Insurance Investments & Financial Services LimitedNYSE: ABTGet Votes) and 17.3% in the first quarter, HoldingsChannel.com reports. The investor owned 1,050 shares of the pharmaceutical maker’s stock after acquiring an additional 155 shares during the period. Harel Insurance Investments & Financial Services Ltd. at Abbott Laboratories was worth $124,000 as of its most recent filing.

A number of other brokerages and hedge funds have also recently made changes to their positions in the business. Consolidated Planning Corp raised its position in shares of Abbott Laboratories by 73.4% during the first quarter. Consolidated Planning Corp now owns 13,368 shares of the health care maker’s stock valued at $1,582,000 after acquiring an additional 5,659 shares in the last quarter. Advisory Alpha LLC raised its position in shares of Abbott Laboratories by 2.0% in the first quarter. Advisory Alpha LLC now owns 5,313 shares of the health care maker’s stock valued at $629,000 after acquiring an additional 106 shares in the last quarter. Verdence Capital Advisors LLC raised its position in shares of Abbott Laboratories by 17.2% in the first quarter. Verdence Capital Advisors LLC now owns 21,338 shares of the health care maker’s stock valued at $2,526,000 after acquiring an additional 3,128 shares in the last quarter. Private Wealth Partners LLC raised its position in shares of Abbott Laboratories by 16.7% during the first quarter. Private Wealth Partners LLC now owns 13,463 shares of the health care maker’s stock valued at $1,593,000 after acquiring an additional 1,930 shares in the last quarter. Finally, SPC Financial Inc. raised its position in shares of Abbott Laboratories by 11.0% in the 1st quarter. SPC Financial Inc. now owns 20,594 shares of the healthcare maker’s stock valued at $2,438,000 after acquiring an additional 2,036 shares during the last quarter. 73.46% of the stock currently belongs to hedge funds and other financial institutions.

Abbott Laboratories Price Performance

Sections a ABT opened at $109.20 on Monday. The company has a market capitalization of $191.20 billion, a price-to-earnings ratio of 22.80, a price-to-earnings-growth ratio of 4.04 and a beta of 0.75. The company has a debt ratio of 0.48, a quick ratio of 1.40 and a current ratio of 1.85. Abbott Laboratories has a one year low of $101.24 and a one year high of $142.60. The fifty day moving average is $110.20 and the 200 day moving average is $117.09.

Abbott Laboratories (NYSE: ABTGet Votes) last announced its earnings results on Wednesday, July 20th. The healthcare provider reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.34. Abbott Laboratories had a profit margin of 29.64% and a margin of 18.78%. The business had revenue of $11.26 billion during the quarter, compared to analysts’ expectations of $10.37 billion. In the same quarter last year, the business posted earnings of $1.17 per share. The company’s revenue for the quarter was up 10.1% on a year-over-year basis. Equities analysts expect that Abbott Laboratories will post 5 EPS for the current year.

Abbott Laboratories announces dividend

The company also announced a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be given a dividend of $0.47 per share. The latest trading day for shares is Thursday, July 14. The company paid $1.88 per share during the last period and the annual yield was 1.72 %. The company Abbott Laboratories Limited contributed 39.25 %.

Insider Activity at Abbott Laboratories

In related news, SVP Randel William Woodgrift sold 24,000 shares of the firm’s stock in a transaction dated Wednesday, May 4. The stock was sold at a price of $113.00, for a total transaction of $2,712,000.00. Following the completion of the transaction, the senior vice president now owns 47,854 shares of the company’s stock, valued at $5,407,502. The sale was disclosed in a document issued by the Securities & Exchange Commission, which is available now this link. In related news, SVP Randel William Woodgrift sold 24,000 shares of the stock in a transaction on Wednesday, May 4th. The stock was sold at a price of $113.00, for a price of $2,712,000.00. Following the completion of the transaction, the vice president now owns 47,854 shares in the company, valued at approximately $5,407,502. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at SEC website. Also, Director Daniel J. Starks sold 50,000 shares of the stock in a transaction on Tuesday, May 3rd. The shares were traded at an average price of $113.22, for a total value of $5,661,000.00. Following the completion of the transaction, the director now owns 6,973,500 shares of the company’s stock, valued at approximately $789,539,670. Disclosures for these products can be found Here. Investors own 0.52% of the company’s stock.

Changes in Analyst Ratings

Several research firms recently issued reports on ABT. Stifel Nicolaus dropped their target price on Abbott Laboratories from $136.00 to $126.00 in a research report on Monday, July 18th. BTIG Research dropped their target price on Abbott Laboratories from $130.00 to $126.00 and set a “buy” rating on the stock in a research report on Monday, July 18th. Cowen dropped their target price on Abbott Laboratories from $150.00 to $130.00 in a research report on Wednesday, July 13th. Royal Bank of Canada lowered their price objective on Abbott Laboratories from $143.00 to $132.00 in a research report on Thursday. Finally, Wells Fargo & Company lowered their price target on Abbott Laboratories from $155.00 to $150.00 and set an “overweight” rating on the stock in a research report on Friday, April 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, Abbott Laboratories currently has a “Moderate Buy” rating and a consensus price target of $133.33.

Profile of Abbott Laboratories

(Get Votes)

Abbott Laboratories, together with its subsidiaries, acquires, develops, manufactures, and markets medical products worldwide. It operates in four divisions: Established Pharmaceuticals, Research, Pharmaceuticals, and Medical Devices. The Established Pharmaceutical Products segment provides drugs for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or stress, gynecological diseases, hormone replacement, dyslipidemia, high blood pressure, hypothyroidism, ulcers, infections heart fever, inflammation, and migraine, and provides anti-infective clarithromycin, flu vaccine, and medication to control the physiological effects of the intestines.

Recommended Articles

Want to see what other hedge funds are holding ABT? Go to HoldingsChannel.com to access the latest 13F filings and internal sales of Abbott Laboratories (NYSE: ABTGet Votes).



Receive Abbott Laboratories News & Reviews Daily – Enter your email address below to receive a concise daily summary of the latest news and expert opinions on Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.